• Belite Bio scheduled oral presentations of topline Phase 3 DRAGON results for tinlarebant in adolescent Stargardt disease.
• Data to be presented July 8 at ISCEV in Sydney, July 18 at the ASRS annual meeting in Montréal.
• Tinlarebant is an oral RBP4 modulator intended to reduce vitamin A–derived bisretinoid toxins linked to retinal degeneration.
• Company previously reported DRAGON met its primary endpoint; tinlarebant remains in DRAGON II for Stargardt disease, PHOENIX for geographic atrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060700PRIMZONEFULLFEED9757188) on July 06, 2026, and is solely responsible for the information contained therein.